| # | Title | Journal | Year | Citations |
|---|
| 1 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Nature | 2010 | 1,610 |
| 2 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature | 2019 | 1,375 |
| 3 | Histone-deacetylase inhibitors: novel drugs for the treatment of cancer | Nature Reviews Drug Discovery | 2002 | 1,335 |
| 4 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Lancet Oncology, The | 2012 | 1,176 |
| 5 | Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study | Lancet, The | 2020 | 1,108 |
| 6 | Functional significance of the perforin/granzyme cell death pathway | Nature Reviews Immunology | 2002 | 994 |
| 7 | Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow | Journal of Cell Science | 2003 | 949 |
| 8 | Translational biology of osteosarcoma | Nature Reviews Cancer | 2014 | 939 |
| 9 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | Lancet Oncology, The | 2011 | 847 |
| 10 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
| 11 | Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k | EMBO Journal | 1997 | 833 |
| 12 | KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours | European Journal of Cancer | 2006 | 810 |
| 13 | Quantitative evaluation ofEscherichia colihost strains for tolerance to cytosine methylation in plasmid and phage recombinants | Nucleic Acids Research | 1989 | 744 |
| 14 | Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells | Nature Medicine | 2001 | 700 |
| 15 | The evolutionary history of 2,658 cancers | Nature | 2020 | 690 |
| 16 | The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer | Journal of Thoracic Oncology | 2007 | 658 |
| 17 | New aspects of natural-killer-cell surveillance and therapy of cancer | Nature Reviews Cancer | 2002 | 655 |
| 18 | A fresh look at tumor immunosurveillance and immunotherapy | Nature Immunology | 2001 | 650 |
| 19 | Phytochelatin Synthase Genes from Arabidopsis and the Yeast Schizosaccharomyces pombe | Plant Cell | 1999 | 645 |
| 20 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab | Annals of Oncology | 2017 | 641 |
| 21 | Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide | Journal of Clinical Investigation | 2003 | 636 |
| 22 | CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity | Nature | 2017 | 624 |
| 23 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Journal of Pathology | 2010 | 617 |
| 24 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death | Journal of Pathology | 2020 | 610 |
| 25 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Lancet Oncology, The | 2018 | 587 |
| 26 | Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice | Journal of Immunology | 2002 | 582 |
| 27 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Nature | 2018 | 572 |
| 28 | MYB function in normal and cancer cells | Nature Reviews Cancer | 2008 | 536 |
| 29 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial | Lancet Oncology, The | 2017 | 535 |
| 30 | Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches | Blood | 2001 | 522 |
| 31 | Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma | Leukemia | 2010 | 505 |
| 32 | Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis | Journal of Experimental Medicine | 2001 | 484 |
| 33 | Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis | Blood | 2001 | 478 |
| 34 | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study | Annals of Oncology | 2009 | 476 |
| 35 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer | Annals of Oncology | 2021 | 454 |
| 36 | Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor | Blood | 2001 | 449 |
| 37 | The Akt kinase signals directly to endothelial nitric oxide synthase | Current Biology | 1999 | 445 |
| 38 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study | Lancet Oncology, The | 2020 | 441 |
| 39 | A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments] | Blood | 1996 | 434 |
| 40 | Options available — from start to finish — for obtaining expression data by microarray | Nature Genetics | 1999 | 433 |
| 41 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors | Clinical Cancer Research | 2016 | 428 |
| 42 | Activating and inhibitory receptors of natural killer cells | Immunology and Cell Biology | 2011 | 426 |
| 43 | Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group | Journal of Clinical Oncology | 2003 | 420 |
| 44 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial | Lancet Oncology, The | 2016 | 418 |
| 45 | Melanoma | Nature Reviews Disease Primers | 2015 | 417 |
| 46 | Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2003 | 414 |
| 47 | Improved double-stranded DNA sequencing using the linear polymerase chain reaction | Nucleic Acids Research | 1989 | 413 |
| 48 | Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling | Cancer Cell | 2009 | 411 |
| 49 | Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development | Journal of Experimental Medicine | 2002 | 407 |
| 50 | Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification | Journal of Thoracic Oncology | 2011 | 407 |
